Market Overview

Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018 -


The "Competitor
Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint
Inhibitors 2018"
report has been added to's

This Competitive Intelligence report analyzes the competitive field of
CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors as of
June 2018 in a tabulated format with structured listings of
industry-relevant data. The report describes the lead indications of
each unique molecule in the most advanced R&D stage and differentiates
between specific and bi- or multispecific molecules.

The mainly selective, but also bispecific new molecular entities
inhibit the negative immune checkpoints, including

  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4;
  • LAG-3 (Lymphocyte Activation Gene 3; CD223)
  • TIM-3 (T-cell Immunoglobulin domain and Mucin domain
    3; HAVCR2)
  • TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
  • B7-H3 (CD276)
  • Others (VISTA: V-region Ig-containing Suppressor of
    T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP:
    Glycoprotein A Repetitions Predominant; PVRIG; B7-H4

Immune checkpoint pathways are often activated to inhibit the nascent
anti-tumor immune response. Immune checkpoint therapies act by blocking
or stimulating these pathways and enhance the body's immunological
activity against tumors. Cytotoxic T lymphocyte-associated molecule-4
(CTLA-4), PD-1, and PD-L1 are the most widely studied and recognized
inhibitory checkpoint pathways. Drugs blocking these pathways are
currently utilized for a wide variety of malignancies and have
demonstrated durable clinical activities in a subset of cancer patients.

This approach is rapidly extending beyond CTLA-4 and PD-1/PD-L1. New
inhibitory pathways are under investigation, and drugs blocking LAG-3,
TIM-3, TIGIT, VISTA, or B7/H3 are being investigated.

At least 35 new molecular entities (NMEs), mostly selective or
increasingly bispecific antibodies, inhibiting negative immune
checkpoints are in clinical development as monotherapy or in combination
with other checkpoint modulators. At least further 19 NMEs are
undergoing IND-enabling studies and numerous preclinical approaches are
under evaluation.

The report includes a compilation of currently active projects in
research and development of mostly recombinant antibodies, targeting
negative immune checkpoints, such as CTLA-4, LAG-3, TIM-3, TIGIT, B7-H3,
addition, the report lists company-specific R&D pipelines of inhibitors
of negative immune checkpoints.

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of

For more information about this report visit

View Comments and Join the Discussion!